|
1
|
Foulkes WD, Ghadirian P, Akbari MR, et al:
Identification of a novel truncating PALB2 mutation and analysis of
its contribution to early-onset breast cancer in French-Canadian
women. Breast Cancer Res. 9:R832007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tonin PN, Mes-Masson AM, Futreal PA, et
al: Founder BRCA1 and BRCA2 mutations in French Canadian breast and
ovarian cancer families. Am J Hum Genet. 63:1341–1351. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oros KK, Ghadirian P, Greenwood CM, et al:
Significant proportion of breast and/or ovarian cancer families of
French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations.
Int J Cancer. 112:411–419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Laberge AM, Michaud J, Richter A, et al:
Population history and its impact on medical genetics in Quebec.
Clin Genet. 68:287–301. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scriver CR: Human genetics: lessons from
Quebec populations. Annu Rev Genomics Hum Genet. 2:69–101. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lalloo F and Evans DG: Familial breast
cancer. Clin Genet. 82:105–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghadirian P, Robidoux A, Zhang P, et al:
The contribution of founder mutations to early-onset breast cancer
in French-Canadian women. Clin Genet. 76:421–426. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tischkowitz M, Sabbaghian N, Hamel N, et
al: Contribution of the PALB2 c.2323C>T [p.Q775X] founder
mutation in well-defined breast and/or ovarian cancer families and
unselected ovarian cancer cases of French Canadian descent. BMC Med
Genet. 14:52013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cavallone L, Arcand SL, Maugard CM, et al:
Comprehensive BRCA1 and BRCA2 mutation analyses and review of
French Canadian families with at least three cases of breast
cancer. Fam Cancer. 9:507–517. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roy R, Chun J and Powell SN: BRCA1 and
BRCA2: different roles in a common pathway of genome protection.
Nat Rev Cancer. 12:68–78. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tischkowitz M and Xia B: PALB2/FANCN:
recombining cancer and Fanconi anemia. Cancer Res. 70:7353–7359.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cote S, Arcand SL, Royer R, et al: The
BRCA2 c.9004G>A (E2002 K) [corrected] variant is likely
pathogenic and recurs in breast and/or ovarian cancer families of
French Canadian descent. Breast Cancer Res Treat. 131:333–340.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pern F, Bogdanova N, Schurmann P, et al:
Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a
hospital-based series of German patients with triple-negative
breast cancer. PLoS One. 7:e479932012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guidugli L, Pankratz VS, Singh N, et al: A
classification model for BRCA2 DNA binding domain missense variants
based on homology-directed repair activity. Cancer Res. 73:265–275.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tischkowitz M, Xia B, Sabbaghian N, et al:
Analysis of PALB2/FANCN-associated breast cancer families. Proc
Natl Acad Sci USA. 104:6788–6793. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guenard F, Pedneault CS, Ouellette G,
Labrie Y, Simard J, Inherit and Durocher F: Evaluation of the
contribution of the three breast cancer susceptibility genes CHEK2,
STK11 and PALB2 in non-BRCA1/2 French Canadian families with high
risk of breast cancer. Genet Test Mol Biomarkers. 14:515–526. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Silver DP, Richardson AL, Eklund AC, et
al: Efficacy of neoadjuvant Cisplatin in triple-negative breast
cancer. J Clin Oncol. 28:1145–1153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fong PC, Boss DS, Yap TA, et al:
Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA
mutation carriers. N Engl J Med. 361:123–134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tutt A, Robson M, Garber JE, et al: Oral
poly (ADP-ribose) polymerase inhibitor olaparib in patients with
BRCA1 or BRCA2 mutations and advanced breast cancer: a
proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hilbers F, Vreeswijk M, van Asperen C and
Devilee P: The impact of next generation sequencing on the analysis
of breast cancer susceptibility: a role for extremely rare genetic
variation? Clin Genet. 84:407–414. 2013. View Article : Google Scholar : PubMed/NCBI
|
